Indian Journal of Critical Care Medicine

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 9 , ISSUE 1 ( January, 2005 ) > List of Articles


Cerebral venous thrombosis: An experience with anticoagulation with low molecular weight heparin

Lalitha V. Pillai, Dhananjay P. Ambike, Satish Nirhale, S. M. K. Husainy, Satish Pataskar

Keywords : Heparin, cerebral venous sinus thrombosis, low molecular weight heparin, oral contraceptive, homocysteine

Citation Information : Pillai LV, Ambike DP, Nirhale S, Husainy SM, Pataskar S. Cerebral venous thrombosis: An experience with anticoagulation with low molecular weight heparin. Indian J Crit Care Med 2005; 9 (1):14-18.

DOI: 10.4103/0972-5229.16263

License: CC BY-ND 3.0

Published Online: 01-09-2009

Copyright Statement:  Copyright © 2005; The Author(s).


Cerebral venous sinus thrombosis [CVST] is often an infrequent cause of neurological dysfunction resulting in admissions in Intensive care units [ICU]. Because of its myriad presentation it may be under diagnosed. Unfractionated Heparin [UFH] has been advocated in treatment but needs frequent monitoring. We studied the clinical profile of patients of cerebral venous sinus thrombosis, use of low molecular weight heparin [LMWH] with emphasis on safety in 64 patients of CVST.

PDF Share
  1. Bousser MG, Cerebral venous thrombosis; nothing, heparin, or local thrombolysis? Stroke 1999;30:481-3.
  2. Allroggen H, Abbott RJ. Cerebral venous sinus thrombosis Postgrad Med J 2000;76;12-5.
  3. Srinivasan K. Ischemic cerebrovasular disease in the young: Two common causes in India. Stroke 1984;15;733-5.
  4. Nagaraja D, Sarma GR. Treatment of cerebral sinus/venous thrombosis. Neurol India 2002;50;2:114-6.
  5. de Bruijn SF, Stam J. For the CVST Study Group. Randomized, placebo controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis. Stroke 1999;30:484-8.
  6. Deschiens M. Coagulation studies, factor V leiden, and anticadiolipin antibodies in 40 cases of cerebral venous thrombosis. Stroke 1996;27;1724-30.
  7. Schaller B, Graf R. Cerebral Venous Infarction: The Pathophysiological Concept. Cerebrovasc Dis 2004;18:179-88.
  8. Bousser MG, Chiras J, Sauron B, et al. Cerebral venous thrombosis. A review of 38 cases. Stroke 1985;116:199-213.
  9. Halpern JP, Morris JG, Driscoll GL. Anticoagulants and cerebral venous thrombosis. Aust N Z J Med 1984;14:643-8.
  10. Nagaraja D, Taly AB, Haridas VT, et al. Heparin in hemorrhagic infarction in cerebral venous sinus thrombosis. J Asso phys India 1998;46:706-7.
  11. Diaz JM, Schiffman JS, Urban ES, Maccario M. Superior sagittal sinus thrombosis and pulmonary embolism: A syndrome rediscovered. Acta Neurol Scand 1992;86:390-6.
  12. Prakash C, Bansal BC. Cerebral venous thrombosis. J Indian Acad Clin Med 2000;5:55-61.
  13. Lensing AWA, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins: A meta-analysis. Arch Intern Med 1995;155;601-7.
  14. Hersh J, Siragusa S, Cosmic B, Ginsberg JS. Low molecular weight heparins [LMWH] in the treatment of patients with acute venous thromboembolism. Thromb Haemost 1995;74:360-3.
  15. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism: The Columbus investigators. N Engl J Med 1997;337:657-62.
  16. Fray JI, Muro GJ, Mcdougall CG, et al. Cerebral venous thrombosis - combined intrathrombus rtpa and intravenous heparin. Stroke 1999;30:489-94.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.